biostudies-literatureRombach IResearch Trainees Coordinating CentreEPANational Institute for Health Research (NIHR)1759720X211057668https://www.ebi.ac.uk/biostudies/studies/S-EPMC8756359biostudies-literatureUnknown13<h4>Introduction</h4>In psoriatic arthritis (PsA), treatment recommendations support first-line use of disease-modifying antirheumatic drugs (DMARDs). There are few treatment strategy trials, and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.<h4>Methods</h4>This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, witTherapeutic advances in musculoskeletal diseaseClinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.PMC8756359CL-2011-02-001CS-2016-16-016EP-C-16-016Coates LCTillett WFrancis ARombach IJadon DWatson MSinomati YTucker LDutton SJfalseClinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.<h4>Introduction</h4>In psoriatic arthritis (PsA), treatment recommendations support first-line use of disease-modifying antirheumatic drugs (DMARDs). There are few treatment strategy trials, and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.<h4>Methods</h4>This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, wit2021-01-01T00:00:00Z20212025-05-29T19:17:06.222Z2022-02-11T16:19:36.305ZS-EPMC87563593503553710.1177/1759720X211057668